



SDI Review Form 1.6

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	2013_IJBcRR_6569
Title of the Manuscript:	The Importance of the RAS Interacting with the HGF/c-Met Receptor System in Hypertensive Type 2 Diabetes Mellitus
Type of the Article	Review

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	In paragraph "2 Formation of.....ligands", authors described AngIV and Ang (3-7)'s affinity i.e. low for AT1 & AT2 receptor subtypes. It is not clear. I suggest to authors to add a table with fully describing ligands affinity to all receptors described in this review. Also, describe the affinity of ARBs Candesartan & R-147176.....mentioned in line 191. This is described as low affinity but it is not clear "How much" .	A table has been added (Table 1) as requested that includes receptor affinities for the native angiotensins, Candesartan and Telmisartan. We could not find affinity values for Candesartan and Telmisartan binding at the AT4 receptor subtype. We agree with this Reviewer that a table aids interpretation of points made in the text.
<u>Optional/General</u> comments	This review paper presents role of Renin-angiotensin system (RAS) in type 2 DM. Authors sequentially described the significant of RAS, its ligands, and the specific receptors of angiotensin and their use in the treatment of type 2 DM. Strong side of this review concerns with the description of novel approaches of HGF/c-Met system to develop new treatments in DM2. Important references related to RAS/HGF/c-Met to DM2 are briefly summarized in the present review. Scientifically the review article is fully suitable for the publication in IJBRR.	